Skip to content
HowShorted

ATOSSA THERAPEUTICS, INC. short interest in 2022

In 2022, ATOSSA THERAPEUTICS, INC.'s disclosed short interest ran from 13.55% of shares outstanding on 14 Jan 2022 to 7.30% on 30 Dec 2022, a change of -6.25 percentage points. The year's high was 15.28% on 29 Apr 2022 and its low 7.30% on 30 Dec 2022, averaging 10.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.91 days on 30 Nov 2022. Full history: ATOSSA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ATOSSA THERAPEUTICS, INC. in 2022

2022 in figures

Start of year
13.55% (14 Jan 2022)
End of year
7.30% (30 Dec 2022)
Change
-6.25 pp
High
15.28% (29 Apr 2022)
Low
7.30% (30 Dec 2022)
Average
10.99%
Highest days to cover
30.91 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

ATOSSA THERAPEUTICS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202213.55%7.64
31 Jan 202213.06%7.42
15 Feb 202213.35%6.75
28 Feb 202213.21%9.2710-K filed, results (8-K)
15 Mar 202214.19%9.21
31 Mar 202213.81%8.11
14 Apr 202214.04%12.49
29 Apr 202215.28%8.01
13 May 202213.54%11.8010-Q filed, results (8-K)
31 May 202212.83%14.22
15 Jun 202212.67%9.74
30 Jun 202210.34%4.59
15 Jul 20229.96%15.62
29 Jul 20229.77%15.98
15 Aug 20229.40%13.9410-Q filed, results (8-K)
31 Aug 20229.29%18.73
15 Sep 20229.02%28.37
30 Sep 20228.89%25.43
14 Oct 20228.37%29.11
31 Oct 20228.27%17.68
15 Nov 20228.25%22.6610-Q filed, results (8-K)
30 Nov 20227.91%30.91
15 Dec 20227.57%17.68
30 Dec 20227.30%15.17

See also: ATOSSA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.